Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials.

Published on Mar 1, 2006in European Urology20.096
路 DOI :10.1016/J.EURURO.2005.12.031
Louis Denis27
Estimated H-index: 27
Abstract Objectives To provide tables that allow urologists to easily calculate a superficial bladder cancer patient's short- and long-term risks of recurrence and progression after transurethral resection. Methods A combined analysis was carried out of individual patient data from 2596 superficial bladder cancer patients included in seven European Organization for Research and Treatment of Cancer trials. Results A simple scoring system was derived based on six clinical and pathological factors: number of tumors, tumor size, prior recurrence rate, T category, carcinoma in situ, and grade. The probabilities of recurrence and progression at one year ranged from 15% to 61% and from less than 1% to 17%, respectively. At five years, the probabilities of recurrence and progression ranged from 31% to 78% and from less than 1% to 45%. Conclusions With these probabilities, the urologist can discuss the different options with the patient to determine the most appropriate treatment and frequency of follow-up.
馃摉 Papers frequently viewed together
2 Authors (A B枚hle, P.R Bock)
#1Anna OrsolaH-Index: 23
#2I. TriasH-Index: 3
Last. I. OrsolaH-Index: 3
view all 8 authors...
Abstract Objectives: This study aimed to determine the prognostic value of depth of lamina propria invasion in initial high-grade T1 bladder tumors. Secondary aims were to evaluate the prognostic significance of concomitant carcinoma in situ (CIS) and the impact of bacillus Calmette-Guerin (BCG) treatment as well as to assess the feasibility of microstaging by pathologists in a community setting. Patients and Methods: Ninety-seven tumors were available for study and were substaged according to i...
#1Shahrokh F. Shariat (UTSW: University of Texas Southwestern Medical Center)H-Index: 136
#2Craig D. Zippe (Cleveland Clinic)H-Index: 59
Last. P.I. Karakiewicz (UTSW: University of Texas Southwestern Medical Center)H-Index: 12
view all 24 authors...
ABSTRACT Purpose: We developed and validated nomograms that accurately predict disease recurrence and progression in patients with Ta, T1, or CIS transitional cell carcinoma (TCC) of the bladder using a large international cohort. Methods: Univariate and multivariate logistic regression models targeted histologically confirmed disease recurrence, and focused on 2,542 patients with bladder TCC from 10 participating centers. Variables consisted of pre-cystoscopy voided urine Nuclear Matrix Protein...
#1Murugesan Manoharan (UM: University of Miami)H-Index: 33
#2Mark S. Soloway (UM: University of Miami)H-Index: 104
Management decisions for a patient with a high-grade T1 urothelial cancer of the bladder are both critical and controversial. The optimal management of these tumors requires an accurate diagnosis including the stage and grade, and careful assessment of prognostic factors. The wide range of available treatment options includes transurethral resection alone, adding intravesical therapy, radical cystectomy, and even possibly chemoradia-tion. Despite advances in the understanding of the biologic beh...
#1Katherine N. MooreH-Index: 27
#2Frederic BlackburnH-Index: 1
Last. Yves FradetH-Index: 71
view all 7 authors...
#1Cheryl T. LeeH-Index: 41
#2James E. MontieH-Index: 82
Last. David P. WoodH-Index: 65
view all 5 authors...
Last. J. Alfred WitjesH-Index: 89
view all 5 authors...
Abstract Objective: To evaluate the difference in prognosis between progressive and primary muscle-invasive bladder cancer. Materials and Methods: From 1986 to 2000, 74 patients with progressive muscle-invasive bladder cancer were identified. Eighty-nine patients with primary muscle-invasive bladder cancer were frequency matched for stage to these patients with progressive disease. Baseline data including patient and tumour characteristics were collected at the time of diagnosis of the muscle-in...
#1Mark S. Soloway (UM: University of Miami)H-Index: 104
#1Changping Zou (UA: University of Arizona)H-Index: 15
#2Sanjay Ramakumar (UA: University of Arizona)H-Index: 10
Last. Monica Liebert (American Urological Association)H-Index: 3
view all 9 authors...
ABSTRACTPurpose: Retinoids modulate the growth and differentiation of normal and malignant epithelial cells in vitro and in vivo. Retinoids and their analogues have been used in animal models and clinical trials of chemoprevention and superficial bladder cancer treatment. Interferons are cytokines that have antiviral, antiproliferative and immunomodulatory function. They are used in many clinical trials for the treatment of different cancers. To identify new effective agents and develop novel ap...
#1George N. Thalmann (University of Bern)H-Index: 75
#2Regula Markwalder (University of Bern)H-Index: 27
Last. Urs E. Studer (University of Bern)H-Index: 85
view all 6 authors...
Purpose: In this retrospective nonrandomized study we compared the long-term outcome in patients with newly diagnosed stage T1G3 bladder cancer treated with transurethral resection and bacillus Calmette-Guerin or immediate cystectomy. Materials and Methods: Of 121 patients with a median age of 67 years (range 36 to 88) diagnosed with primary T1G3 bladder cancer between 1976 and 1999, 92 were treated by transureteral resection with additional intravesical bacillus Calmette-Guerin and 29 were trea...
#1Vincenzo Serretta (University of Palermo)H-Index: 23
#2Carlo Pavone (University of Palermo)H-Index: 14
Last. Michele Pavone-Macaluso (University of Palermo)H-Index: 25
view all 6 authors...
Abstract Objectives: To evaluate a highly selected population of patients affected by T1G3 bladder transitional cell carcinoma (TCCB) treated by transurethral resection (TUR) and adjuvant intravesical chemotherapy. Materials and Methods: Between January 1976 and April 1999, 137 patients with T1G3 TCCB were treated by TUR plus intravesical chemotherapy. Particularly, a sequential combination of mitomycin C (MMC) and epirubicin (EPI) was adopted in 91 patients (66.4%). The main exclusion criteria ...
Cited By1928
#1Nassib Abou Heidar (AUB: American University of Beirut)H-Index: 4
#2Muhieddine Labban (AUB: American University of Beirut)H-Index: 4
Last. Rami Nasr (AUB: American University of Beirut)H-Index: 7
view all 7 authors...
The optimal surveillance method for recurrence of non-muscle invasive bladder cancer (NMIBC) after intravesical BCG treatment is unknown. The aim of this study is to assess the difference between two surveillance methods: cystoscopy with bladder biopsies and office-based flexible cystoscopy in detecting NMIBC recurrence and time to recurrence. Charts of patients who underwent transurethral resection of bladder tumor with subsequent intravesical Bacillus Calmette鈥揋uerin (BCG) treatment were revie...
#1Mohamad Nidal Khabaz (KAU: King Abdulaziz University)H-Index: 9
#2Imtiaz Ahmad Qureshi (KAU: King Abdulaziz University)H-Index: 5
Last. Jaudah Al-Maghrabi (KAU: King Abdulaziz University)H-Index: 23
view all 3 authors...
This study examined leptin expression in cases of bladder cancer and its diagnostic and prognostic usefulness in bladder malignancies.A set of 128 urinary bladder cancer cases and 24 normal specimens of bladders were employed for an immunohistochemical investigation of leptin expression in tissue microarrays.Leptin was up-regulated during transformation and was identified as brown cytoplasmic granules in the malignant urothelium of 123 (96%) bladder neoplasms, of which 68 (53.1%) cases showed hi...
#2Philippe Lamy (Aarhus University Hospital)H-Index: 29
Last. Lars Dyrskj酶t (Aarhus University Hospital)H-Index: 64
view all 9 authors...
Abstract null null Background null Currently, no biomarkers of response to mitomycin C have been identified in non鈥搈uscle-invasive bladder cancer patients. Predictive biomarkers could improve the treatment outcome and eliminate adverse events from unnecessary treatment. null null null Objective null To identify and validate predictive biomarkers of chemoresection with mitomycin C. null null null Design, setting, and participants null The intervention group of a randomised controlled trial was id...
#2Il Do HaH-Index: 9
Last. Kevin BurkeH-Index: 5
view all 3 authors...
We consider a parametric modelling approach for survival data where covariates are allowed to enter the model through multiple distributional parameters, i.e., scale and shape. This is in contrast with the standard convention of having a single covariate-dependent parameter, typically the scale. Taking what is referred to as a multi-parameter regression (MPR) approach to modelling has been shown to produce flexible and robust models with relatively low model complexity cost. However, it is very ...
#1Lukas P眉llen (University of Duisburg-Essen)H-Index: 3
#2Cordelia Kaspar (University of Duisburg-Essen)H-Index: 1
Last. Stephan Tschirdewahn (University of Duisburg-Essen)H-Index: 11
view all 11 authors...
OBJECTIVE Patients with bladder cancer (BC) are at risk of developing upper tract urothelial carcinoma (UTUC). Therefore, CT urography is recommended for follow-up. To avoid intravenous contrast agents, retrograde pyelography (RPG) is an alternative. However, it is still unclear whether RPG increases the incidence of UTUC. The aim of this study was to investigate the impact of RPG in the presence of BC on the risk of developing UTUC. PATIENTS AND METHODS Retrospectively analysing a total of 3,68...
#1Raed A. AzharH-Index: 10
#2Anmar M. NassirH-Index: 8
Last. Mohamed A. ElkoushyH-Index: 17
view all 7 authors...
Objective. To observe the clinical effect of Xiaozheng Decoction combined with bladder perfusion with hydroxycamptothecin in the treatment of bladder cancer. Methods. A total of 92 bladder cancer patients admitted to our hospital from January to December 2018 were selected and divided into an observation group and a control group according to the random number table method, with 46 cases in each group. The observation group was given Xiaozheng Decoction combined with bladder perfusion with hydro...
#2Alexey MartovH-Index: 2
Last. P. Laguna (Istanbul Medipol University)H-Index: 4
view all 14 authors...
Purpose null White light (WL) is the traditional imaging modality for transurethral resection of bladder tumour (TURBT). IMAGE1S is a likely addition. We compare 18-mo recurrence rates following TURBT using IMAGE1S versus WL guidance. null Methods null Twelve international centers conducted a single-blinded randomized controlled trial. Patients with primary and recurrent non-muscle-invasive bladder cancer (NMIBC) were randomly assigned 1:1 to TURBT guided by IMAGE1S or WL. Eighteen-month recurre...
#1Zhipeng Xu (SEU: Southeast University)H-Index: 3
#2Hui Chen (Nanjing Medical University)
Last. Ming Chen (SEU: Southeast University)H-Index: 17
view all 6 authors...
Bladder cancer (BLCA) is one of the most common cancers worldwide with high recurrence rate. Hence, we intended to establish a recurrence-related long non-coding RNA (lncRNA) model of BLCA as a potential biomarker based on multi-omics analysis. Multi-omics data including copy number variation (CNV) data, mutation annotation files, RNA expression profiles and clinical data of The Cancer Genome Atlas (TCGA) BLCA cohort (303 cases) and GSE31684 (93 cases) were downloaded from public database. With ...
#3William U. Shipley (Harvard University)H-Index: 102
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.